A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis

A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis

Capmatinib (CMB) is an orally bioavailable mesenchymal–epithelial transition (MET) inhibitor approved by the US-FDA to treat metastatic non-small cell lung cancer (NSCLC) patients, with MET exon 14 skipping mutation. The current study aimed to establish a specific, rapid, and sensitive ultra-perform...

Full description

Bibliographic Details
Main Authors: Mohamed W. Attwa, Ali S. Abdelhameed, Aishah M. Alsibaee, Adnan A. Kadi
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Separations
Subjects:
capmatinib
in vitro half-life
metabolic stability
intrinsic clearance
UPLC-MS/MS
P450 model
Online Access:https://www.mdpi.com/2297-8739/10/4/247

Internet

https://www.mdpi.com/2297-8739/10/4/247

Similar Items